Nucleoside-lipid-based nanoparticles for cisplatin delivery

ACS Nano. 2011 Nov 22;5(11):8649-55. doi: 10.1021/nn202291k. Epub 2011 Oct 11.

Abstract

The use of delivery vehicles to selectively transport anticancer agents to tumors is very attractive to address both toxicity and efficacy issues. We report a novel approach based on hybrid nucleoside-lipids allowing the efficient encapsulation and delivery of cisplatin. We demonstrate that the nucleoside polar heads guide the self-assembly of the aggregates into highly loaded and stable nanoparticles. The nanoparticles, which are efficient vehicles for the delivery of cisplatin into different sensitive and resistant cancer cell lines, can overcome the disadvantages and limitations of drug delivery systems previously reported.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antineoplastic Agents* / metabolism
  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Cisplatin* / metabolism
  • Cisplatin* / pharmacology
  • Drug Carriers / chemistry*
  • Humans
  • Lipids / chemistry*
  • Nanoparticles / chemistry*
  • Nanotechnology
  • Nucleosides / chemistry*

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Lipids
  • Nucleosides
  • Cisplatin